Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Richard J. Daly joins AQST’s Board October 14, 2026, as a Class I director serving through the 2028 annual meeting.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Richard J. Daly joins AQST’s Board October 14, 2026, as a Class I director serving through the 2028 annual meeting
- Board expands from seven to eight directors, with seven independent directors following the appointment
- Daly’s independence under Nasdaq rules strengthens governance oversight and board expertise
- Initial equity award of 57,000 stock options, vesting annually in one-third increments beginning one year after grant
- Options priced at the Common Stock’s closing market price on the Grant Date, limiting immediate dilution economics
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.